Apellis Pharmaceuticals, Inc. (APLS) Sets All-Time High

April 16, 2018 - By Gwen Gough

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) reached $29.75 price per share on Apr, 16, also an all time high. This technical setup was posted by Barchart.com. It has $1.50B MC. At $30.64 target, the company’s valuation could be $44.94 million more.

APLS reached $29.748 on during the last trading session after $3.018 change.Currently Apellis Pharmaceuticals, Inc. is after 0.00% change in last April 16, 2017. APLS has 110,980 shares volume. The stock underperformed the S&P 500 by 11.55%.

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases.The firm is valued at $1.50 billion. The Company’s lead product candidates include APL-2 and APL-1, to treat paroxysmal nocturnal hemoglobinuria, geographic atrophy, intermediate age-related macular degeneration, and chronic obstructive pulmonary disease.Last it reported negative earnings. The firm develops APL-2 for subcutaneous injection, which is an injection into the tissue under the skin, and for intravitreal injection that is an injection into the eye, as well as APL-1 for inhaled administration.

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.